Filing Flows › Neurocrine Biosciences (NBIX) › Guidance history
Neurocrine Biosciences (NBIX) guidance history: what it guided and what it reported
Neurocrine Biosciences gave guidance in 12 earnings releases on file since Feb 7, 2024. Its releases raised guidance 5 times and lowered it once.
Revenue
Every guided period is still to be reported.
| Period | Guided (and how it moved) | Reported | Result | vs midpoint |
|---|---|---|---|---|
| FY2026 | $2.8B–$2.9B (Jul 30, 2026) → raised $2.9B–$2.9B (Nov 2, 2026) | — | to be reported | — |
Stock-based compensation
This line is not in the statements Filing Flows reads, so there is no reported figure to hold it to.
| Period | Guided (and how it moved) | Reported | Result | vs midpoint |
|---|---|---|---|---|
| FY2024 | $75.0M (Feb 7, 2024) → lowered $65.0M (May 1, 2024) | — | — | — |
Adjusted stock-based compensation
The guide is on an adjusted basis that the GAAP statements do not show, so there is no reported figure to hold it to.
| Period | Guided (and how it moved) | Reported | Result | vs midpoint |
|---|---|---|---|---|
| FY2026 | $90.0M (Feb 11, 2026) → reaffirmed $90.0M (May 5, 2026) → raised $115M (Jul 30, 2026) → reaffirmed $115M (Nov 2, 2026) | — | to be reported | — |
| FY2025 | $70.0M (Feb 6, 2025) → raised $85.0M (May 5, 2025) → reaffirmed $85.0M (Jul 30, 2025) → raised $90.0M (Oct 28, 2025) | — | — | — |
| Q4 2024 | $65.0M (Oct 30, 2024) | — | — | — |
| FY2024 | $65.0M (Aug 1, 2024) | — | — | — |
The latest quarter
Neurocrine Biosciences, Q3 2026: revenue $1.1B (+41% year over year), operating margin 29.5%, net earnings $206M, operating cash flow $395M. The chart follows the revenue to costs, profit and cash.
Questions
Does Neurocrine Biosciences beat its guidance?
Neurocrine Biosciences gave guidance in 12 earnings releases on file since Feb 7, 2024. Its releases raised guidance 5 times and lowered it once.
How often does Neurocrine Biosciences raise guidance?
Its earnings releases raised guidance 5 times and lowered it once since Feb 7, 2024.
Each guided period is held to the last guidance given before its figures were reported; a single figure counts as in line within 1% (0.25 pts for a rate). Reported figures are GAAP, from the company's filings; adjusted guidance shows its moves only.